Adobe stock photos - nadiaCSL has signed an option and collaboration agreement with VarmX valued at up to US$2.2bn. The company will pay US$117m upfront and will fund a global Phase III trial of VMX-C001.
Tag Archive for: partnership
Rosa Therapeutics IncMonte Rosa Therapeutics Inc, founded in Basel in 2018, can look forward to an upfront payment of US$120m for its second collaboration and licensing deal with Novartis AG to develop protein degraders. A total of US$5.7bn is on the table for the new development of an anti-inflammatory candidate that is not part of Monte Rosa’s pipeline.
FRAXA Ewsearch OrganisationIn a US$450m deal with UK-based Kaerus Bioscience Ltd, Servier SA has acquired the development and commercialisation rights to KER-0193, a Phase II-ready drug candidate for the treatment of rare Fragile X syndrome, the most common monogenic cause of autism.
Polpharma Biologics SAPolpharma Biologics SA and MS Pharma SA have signed licensing agreements for Polpharma’s vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars in the Middle East and North Africa (MENA) region.
Solar FoodsAfter Finnish protein powder producer Solarfoods signed a strategic agreement with two US food manufacturers to supply 6,000 tonnes of Solein from 2030 onwards, the company has now announced a more concrete partnership with US flavour manufacturer Sensapure Flavours Inc.
Unnatural Products IncCalifornia oral macrocyclic peptide specialist Unnatural Products, Inc. and Dutch-Belgian Argenx SE have formed a multi-target research collaboration aimed at developing oral macrocyclic peptide drugs with UNP’s synthetic macrocycle platform.
adobe stock - aliaksandrBritish cell and gene therapy CDMO eXmoor Pharma plc, and KU Leuven which has just launched a translational cell and gene therapy hub in Belgium have inked a strategic collaboration supporting the hub’s work in four areas.
Building on the January 2025 ALS drug discovery collaboration with Alchemab Therapeutics, Eli Lilly & Company has secured rights to the first IND-ready program under a US$415m licensing agreement.
adobe stock - JHVEPhoto Boehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.
Menarini GroupFrench ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development.